Rituximab, lenalidomide, and ibrutinib in relapsed/refractory primary cutaneous diffuse large B‐cell lymphoma, leg type
Authors:
Open Access
- 12 October 2021
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 196 (4) , e30-e33
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Ibrutinib plus lenalidomide and rituximab has promising activity in relapsed/refractory non–germinal center B-cell–like DLBCLBlood, 2019
- The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomasBlood, 2019
- A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg TypeJournal of Investigative Dermatology, 2018
- Clinicopathologic significance of MYD88 L265P mutation in diffuse large B-cell lymphoma: a meta-analysisScientific Reports, 2017
- Combination of ibrutinib and chemotherapy produced a durable remission in multiply relapsed diffuse large B-cell lymphoma leg type with mutant MYD88 and wildtype CD79Haematologica, 2017
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphomaNature Medicine, 2015
- High Frequency and Clinical Prognostic Value of MYD88 L265P Mutation in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg-TypeJAMA Dermatology, 2014
- Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trialLeukemia, 2013
- Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell LymphomaCancer Cell, 2012
- Oncogenic MYD88 mutation drives Toll pathway to lymphomaImmunology & Cell Biology, 2011